Search hospitals > Ontario > TORONTO
Centre for Addiction and Mental Health
Claim this profileTORONTO, Ontario M5T 1R8
Global Leader in Depression
Global Leader in Schizophrenia
Conducts research for Major Depressive Disorder
Conducts research for Psychosis
Conducts research for Mental Illness
279 reported clinical trials
36 medical researchers
Summary
Centre for Addiction and Mental Health is a medical facility located in TORONTO, Ontario. This center is recognized for care of Depression, Schizophrenia, Major Depressive Disorder, Psychosis, Mental Illness and other specialties. Centre for Addiction and Mental Health is involved with conducting 279 clinical trials across 199 conditions. There are 36 research doctors associated with this hospital, such as Daniel Blumberger, MD, Ariel Graff, MD, PhD, Philip Gerretsen, MD, PhD, and Bernard Le Foll, MD.Top PIs
Daniel Blumberger, MDCentre for Addiction and Mental Health7 years of reported clinical research
Studies Depression
Studies Major Depressive Disorder
11 reported clinical trials
21 drugs studied
Ariel Graff, MD, PhDCentre for Addiction and Mental Health1 year of reported clinical research
Studies Schizophrenia
Studies Coronavirus
7 reported clinical trials
10 drugs studied
Philip Gerretsen, MD, PhDCentre for Addiction and Mental Health1 year of reported clinical research
Studies Schizophrenia
Studies Coronavirus
7 reported clinical trials
10 drugs studied
Bernard Le Foll, MDCenter for Addiction and Mental Health3 years of reported clinical research
Studies Alcohol Consumption
Studies Alcoholism
5 reported clinical trials
6 drugs studied
Clinical Trials running at Centre for Addiction and Mental Health
Depression
Schizophrenia
Bipolar Disorder
Alcoholism
Major Depressive Disorder
Attention Deficit Hyperactivity Disorder (ADHD)
Psychosis
Alcohol Consumption
Cannabis Abuse
Mental Illness
Escitalopram + Brexpiprazole
for Depression
This is a study that will test a predictive biomarker algorithm based on results from a previous study. The goal of this study is to integrate clinical, imaging, EEG, and molecular data across 8 sites to predict treatment outcome for patients experiencing a major depressive episode (MDE).
Recruiting3 awards Phase 48 criteria
Cannabis Abstinence
for Depression
The prevalence of major depressive disorder (MDD) is \~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold compared to 2.9% in the general population, and is associated with poorer treatment outcomes and impaired cognitive and psychosocial functioning in comparison to MDD patients without CUD. Most studies of cannabis use in MDD are cross-sectional in design, and therefore causal relationships are unclear. This study investigates the effects of cannabis abstinence over a 28-day period in patients with MDD with co-occurring CUD using a randomized controlled design, namely contingent reinforcement.
Recruiting1 award N/A
Positive Parenting Techniques
for Depression
Children with emotional and behavioural difficulties (EBD) experience disproportionate social, family and academic impairment and have between two to five times increased likelihood of developing an anxiety disorder, mood disorder or other severe mental illness in adolescence and adulthood. There is a close association between parental depression and the emergence and maintenance of childhood EBD that is likely bidirectional. Parents of children with EBD experience disproportionate stress, increasing their risk for depression; yet chronic and untreated parental depression is associated with the emergence of child EBD in the first place. Therefore, designing targeted and effective assessment and treatment for parents of children with EBD that take into account parents' depression is necessary. Of pressing concern, first-line Behavioral Parent Training (BPT) treatments for parents of children with EBD are not tailored to parent's mental health needs, which may be why upwards of 40 percent of parents and children treated in these programs fail to sufficiently benefit. Existing research highlights emotional and cognitive factors that may differentiate depressed parents from non-depressed parents that may be treatment targets to improve outcomes for depressed parents and children. The main aim of the proposed project is to evaluate the feasibility and acceptability of a novel targeted treatment for depressed parents of children with EBD, along with adherence to study protocol. The investigators will use the results of the pilot study to make key modifications to study procedures and the treatment itself to increase the success of a future randomized controlled trial (RCT) to test treatment efficacy. The investigators hypothesize that: 1. Recruitment will be feasible. 2. The intervention will be acceptable, and there will be a high rate of adherence to study protocol.
Recruiting1 award N/A4 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Centre for Addiction and Mental Health?
Centre for Addiction and Mental Health is a medical facility located in TORONTO, Ontario. This center is recognized for care of Depression, Schizophrenia, Major Depressive Disorder, Psychosis, Mental Illness and other specialties. Centre for Addiction and Mental Health is involved with conducting 279 clinical trials across 199 conditions. There are 36 research doctors associated with this hospital, such as Daniel Blumberger, MD, Ariel Graff, MD, PhD, Philip Gerretsen, MD, PhD, and Bernard Le Foll, MD.